Pegylated Glucose Gold Nanoparticles for Improved In-Vivo Bio-Distribution and Enhanced Radiotherapy on Cervical Cancer
The DOI matches its Crossref record.
Abstract
Pharmacokinetics and bio-distribution are crucial factors affecting the performance of an intravenous drug. In this study, we explore the combined use of glucose and polyethylene glycol (PEG) ligands to further improve gold nanoparticle (GNP) pharmacokinetics and bio-distribution, with the aim of using the drug for in-vivo radiotherapy. The inclusion of PEG was found to significantly prolong the half-life period, where PEG-Glu-GNPs achieved 6.17 +/- 3.71 h, compared to 1.23 +/- 0.14 h for Glu-GNPs and 1.07 +/- 0.22 h for uncoated GNPs. Our data indicates that nanoparticle size impacts cell uptake performance, with 20 nm being the optimal diameter for cancer treatment applications. Although PEG-Glu-GNPs mainly distributed in the spleen, liver, lung, and kidneys, the concentration of PEG-Glu-GNPs in tumour tissue was 20 times higher than healthy cells in the uterus and ovaries, reaching 9.22 +/- 2.41 microg/g cancer tissue at 48 h after injection. This difference in uptake holds promise for selective tumor targeting which can in turn lead to more effective radiotherapy through the interaction of X-rays and GNPs. Specifically tumor size after 47 days of treatment had reduced to (769 +/- 92) mm3 compared to (1432 +/- 269) mm3 using X-rays alone and (3514 +/- 1818) mm3 without any treatment. Moreover, the mice remained healthy without statistically significant weight loss. Results of our pharmacokinetic and bio-distribution study as well as therapeutic data for PEG-Glu-GNPs in our tumor bearing animal model demonstrate that PEG-Glu-GNPs provide excellent in-vivo stability, tumor targeting function, and radiotherapeutic enhancement effects, providing useful insights for further clinical studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Gold nanoparticles for applications in cancer radiotherapy: Mechanisms and recent advancements
Her, S., Jaffray, D. A., & Allen, C. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.12.012 · Cited by 865
Stepien, G., Moros, M., Pérez-Hernández, M., Monge, M., Gutiérrez, L., Fratila, R. M., las Heras, M. D., Menao Guillén, S., Puente Lanzarote, J. J., Solans, C., et al. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b18648 · Cited by 158
Ghahremani, F., Kefayat, A., Shahbazi-Gahrouei, D., Motaghi, H., Mehrgardi, M. A., & Haghjooy-Javanmard, S. (2018) · Nanomedicine · doi:10.2217/nnm-2018-0180 · Cited by 70
Kefayat, A., Ghahremani, F., Motaghi, H., & Mehrgardi, M. A. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.01.037 · Cited by 54
Zhao, N., Yang, Z., Li, B., Meng, J., Shi, Z., Li, P., & Fu, S. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s104034 · Cited by 51
Metadata
- Authors
- Geng, F., Xing, J. Z., Chen, J., Yang, R., Hao, Y., Song, K., & Kong, B.
- Venue
- Journal of Biomedical Nanotechnology
- Publisher
- American Scientific Publishers
- Published
- 2014-07-01
- Volume
- 10
- Issue
- 7
- Pages
- 1205-1216
- ISSN
- 1550-7033 (ISSN-L)
- OpenAlex
- W2324603849
- Cited by
- 49
- References
- 0
- FWCI
- 4.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.